anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients randomized to the "BiV pacing with MPP and SyncAV" study arm will have CRT programming to biventricular pacing with MPP activated. RV-LV pacing delay set to 5 ms, LV1 \& LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration).
The phase I portion of the study is a standard dose-escalation schemed designed to determine the maximum tolerated dose (MTD) of the combination of bortezomib, cladribine, and rituximab therapy. The MTD is defined as the dose level in which ≤1 out of 6 patients have dose-limiting toxicity (DLT). Three patients are enrolled on a dose level. If 0 out of 3 patients have DLT, then the next set of 3 patients are enrolled at the next highest dose level. If ≥2 out of 3 patients have DLT, then the MTD will have been exceeded and dose escalation will cease. Three additional patients will be enrolled at the next lowest dose level if only 3 were treated previously at that level. If 1 out of 3 patients have DLT, then the next set of 3 patients will be treated at the same dose level. If ≤1 out of 6 patients treated at that dose level have DLT, then the next set of patients will be treated at the next higher dose level. If ≥2 out of 6 patients treated at that dose level have DLT, then the MTD will have been exceeded and dose escalation will cease. Three additional patients will be treated at the next lowest dose level if only 3 were treated previously at that level. This phase I study will use 3 dose levels of cladribine (3 mg/m2, 4 mg/m2, and 5 mg/m2), with 3 mg/m2 being the starting dose level. DLTs will be assessed at the completion of the first 2 cycles of cladribine and rituximab.

Phase II Design: The phase II portion of the study is a two-arm, single-stage design with no interim analysis. One arm will accrue newly diagnosed patients, and one arm will accrue relapsed patients. In each arm, the progression-free survival rate at 2 years will be used as the primary endpoint for determining whether the treatment is sufficiently active in each arm. No comparisons will be made between the arms.

Due to difficulties with enrollment, this trial will not move into the intended Phase II of the proposed Phase I/II study. This study will only be Phase I.
The invention discloses a platinum anticancer oxaliplatin composition, belonging to the technical field of medicines. The composition comprises oxaliplatin and sodium dihydrogen phosphate, wherein oxaliplatin is a crystal. An X-ray powder diffraction pattern obtained through measurement by using a Cu-Kalpha ray is shown in a drawing 1 in the specification. A new crystal form of oxaliplatin provided by the invention is different from the crystal structure of the prior art. Through experimental verification, the compound in the new crystal form has high purity, good flowability and stability and low impurity content, has low possibility of moisture absorption and is safe and reliable to apply clinically. Powder injections prepared by utilizing the compound in the new crystal form have good stability after undergoing compatibility with solvents, have low content of insoluble particles and are very suitable to apply clinically.
The invention is a manufacturing method for a disease-prevention and healthy keeping cigarette which is made up of several kinds of tobaccos and several kinds of Chinese medicine and who can cure respiratory system diseases. It is made up of two kinds of tobaccos and seven kinds of Chinese medicines according to weight proportion 5:0.5-5, which can be divided into following three kinds of breeds: 1. flue-cured tobacco type 2. Compound type 3. Cigar type, it can develop several kinds of breeds. The Chinese medicines are made up of mulberry leaf, wild chrysanthemum flower, stigma of corn, cutification, orange silk, catnip, all of which can reduce the nicotine and tar in tobacco. It can achieve the healthy keeping effect with Chinese medicine fuming.
Addition of lectins to the peritoneal lavage liquid or i.p. administration of lectins is able to have a beneficial effect in particular on early acute pancreatitis (blocking of the hormone receptors, less susceptibility of the pancreatic cells to stimulation, lessening of activity of the pancreatic gland, reduction in the serum enzyme levels). Nowadays the digestive action of the pancreatic enzymes in the abdominal cavity is minimised and flushed out by adding enzyme inhibitors (trypsin inhibitors, e.g. aprotinin). Lectins are able to reach the pancreatic gland directly or indirectly from the abdominal cavity and then block the stimulating hormone receptors. This protects the gland from self-digestion additionally and earlier than with enzyme inhibitors. Wheat germ lectin (WGA) as additive to the lavage fluid in peritoneal lavage combines with the CCK receptor and other stimulating surface receptors of the pancreatic cells and blocks these so that stimulation by pathophysiological ligands (CCK, secretin, nervous effects) cannot take place. Undigested, undamaged parenchymal portions can thus be protected from further autodigestion. For the therapy in particular of acute, necrotising pancreatitis in the early stage or acute episodes of chronic pancreatitis in internal medicine, surgery, intensive care with or without peritoneal lavage.
Repeated sevoflurane exposure in neonatal mice triggers neuroinflammation with detrimental effects on cognitive function. Yet, the mechanism of the sevoflurane-induced cytokine response is largely unknown. In this study, we reveal that 3-MA, an autophagy inhibitor, attenuated the sevoflurane-induced neuroinflammation and cognitive dysfunction, including the decreased freezing time and fewer platform crossings, in the neonate mice. 3-Methyladenine (3-MA) suppressed sevoflurane-induced expression of interleukin-6 and tumor necrosis factor-alpha in vitro. Moreover, sevoflurane activates IRF3, facilitating cytokine transcription in an AKT3-dependent manner. Mechanistically, sevoflurane-induced autophagic degradation of dehydrocholesterol-reductase-7 (DHCR7) resulted in accumulations of its substrate 7-dehydrocholesterol (7-DHC), mimicking the effect of sevoflurane on AKT3 activation and IRF3-driven cytokine expression. 3-MA significantly reversed sevoflurane-induced DHCR7 degradation, AKT phosphorylation, IRF3 activation, and the accumulation of 7-DHC in the hippocampal CA1 region. These findings pave the way for additional investigations aimed at developing novel strategies to mitigate postoperative cognitive impairment in pediatric patients.
Pediatric care professionals and parents seek safe ways to make invasive medical procedures less stressful and traumatic for children. However, for unpleasant procedures that require child cooperation, this task becomes difficult. Home-training in self-hypnotic relaxation may provide an inexpensive, yet systematic method for improving the overall medical care of children undergoing invasive medical procedures. The proposed study is designed to utilize a self-hypnosis DVD home-training program for parents to use with their children to teach self-hypnosis techniques for inducing relaxation and hypnotic analgesia. The study will examine the efficacy of this intervention for children undergoing urethral catheterization for VCUG procedures. Parents will be instructed to watch the DVD and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure. Both parents and children will be asked to complete a series of questionnaires before and following the procedure.
Application of the experimental group The women in the experimental group will be informed about the function, click points and application of EFT through a written material. The EFT application will be explained practically by a certified researcher and the application steps will be followed. Women who underwent EFT will be contacted again within a week or two and asked how they feel and feedback will be received about whether the problem or problems during the first meeting still bother them. By asking women to show how they feel on the SUE scale, the EFT application will be repeated until the woman expresses positive emotions on the SUE scale. The number of EFT applications will be decided according to the woman's condition. After the EFT application is completed, the woman will be re-evaluated with VAS and PSS in the 1st and 2nd months. It will be recorded and reported as perceived stress when assessing The EFT practitioner researcher's certification is S.E.M. It is a certificate with a total scope of 50 hours, including face-to-face training, issued by the Academy considering International Education standards and criteria. The training was given by a trainer with a trainer certificate on EFT. The researcher, who has a nationally and internationally valid certificate, has prepared a guideline in parallel with the training he has received, received expert opinions on the guideline and will carry out its pilot application.

Application of the control group A meeting will be held with the women in the control group at the beginning of the research and information will be given about the study. The researcher will open a WhatsApp group for the women in the control group and follow them to eliminate their lack of information. Throughout the research, women in the control group will continue their routine coping habits regarding dysmenorrhea and perceived stress levels, and this group, like the experimental group, will be re-evaluated with VAS and PSS in the 1st and 2nd months of the research.
One hour before the operation,warm socks will be put on the experimental group,body temperature,heart rate,blood pressure,SPO2 will be measured and recorded every fifteen minutes.During the surgery,body temperature,heart rate,blood pressure,SPO2 value, drainage amount will be measured and recorded every fifteen minutes.The patient will be transferred to the postoperative care unit with warm socks and will stay on his feet in the postoperative care unit.Body temperature, heart rate,blood pressure,SPO2 values will be recorded every fifteen minutes.He will be transferred from the postoperative care unit to the clinic with socks.will stay. After transferring to the bed,body temperature,heart rate, arterial blood pressure, SPO2 will be recorded every fifteen minutes for a total of 180minutes.Chills,chills and the total drainage amount for 24hours will be recorded in the same section.
Sepsis-associated encephalopathy (SAE) is a severe complication of sepsis, characterized by neuroinflammation, mitochondrial dysfunction, and oxidative stress, leading to cognitive decline and high mortality. The effectiveness of dichloroacetate (DCA) in modulating mitochondrial function provides a novel therapeutic strategy for SAE. In this study, we evaluated the neuroprotective effects of DCA in a rat model of SAE induced by cecal ligation and puncture (CLP). Rats treated with DCA exhibited significant improvements in neurological function and survival, as evidenced by less neuron loss from histopathologic analysis, restored neurologic deficit scores, improved Y-maze alternation percentages, and enhanced recognition index performance. Biochemical analyses showed that DCA administration at 25 mg/kg and 100 mg/kg reduced astrocyte and microglial activation, indicating reduced neuroinflammation. Furthermore, DCA simultaneously reduced the production of circulating and cerebral inflammatory cytokines (including TNF-α, IL-1β, and IL-10), concomitant with mitigating oxidative stress through down-regulating expression of 8-Hydroxy-2'-deoxyguanosine (8-OHdG) and reactive oxygen species (ROS) in the brain. Mechanistically, DCA modulated mitochondrial dynamics by suppressing Drp1 and pDrp1 expression, which are indicators of mitochondrial fission. This was corroborated by transmission electron microscopy, quantification of mitochondrial area, and Western blot analyses. Furthermore, DCA treatment improved ATP levels, mitochondrial complex I activity, and NAD+/NADH ratio, indicating a significant attenuation of brain mitochondrial dysfunction. In conclusion, our findings suggest that DCA confers neuroprotection in SAE by curtailing neuroinflammation and mitochondrial fission, outlining a promising therapeutic strategy for treating SAE in critically ill patients.
Patients and healthcare professionals in the control practices will provide and receive usual care according to the national guidelines for T2DM of the Dutch College of General Practitioners (NHG). Participants in the control practices will not have access to the multistage SDM program.
The identification of blood tests that detect patients having disability provoking Multiple Sclerosis (MS) relapses in real time could lead to a new era of MS relapse treatment. The cross-talk between inflammatory and coagulation pathways in multiple sclerosis has been recognized on some level for decades. Accidental and anecdotal clinical observations suggest that excessive activation of the intrinsic coagulation pathway, namely with increased Factor VIII activity, occurs with some MS relapses, and that these are the relapses that don't recover with current standard of care treatments, leaving behind permanent disability.

To test this hypothesis that real time abnormally increased levels of Factor VIII activity related labs can identify disabling relapses in real time, nine adult patients with relapsing remitting MS with or without secondary progression will be consented and enrolled in this observational, longitudinal clinical trial. Patients will receive standard of care treatment per the investigator's discretion for their relapse, but will have additional blood tests testing Factor VIII activity, Factor VIII antigen, serum neurofilament among others drawn on days 1, 8, 22 and 90 of the study. The investigator and the patient will not know these lab test results. Patients will also have mris of the brain, cervical spine, and thoracic spine done with and without contrast as soon as possible upon study entry. On Days 1,8,22, and 90, in addition to blood tests, the patient will complete an EDSS and MSFC (that looks at ambulation, hand/arm coordination, and cognitive function, comprised of the 25 foot timed walking tests, with and without any assistive devices if possible), and fill out a recovery survey. Individual blood tests, aggregate blood tests, mri findings, EDSS and MSFC individual and summed scores will be scrutinized and evaluated for the ability to identify a MS relapse and to identify a treatment-resistant MS relapse
Bacterial vaginosis (BV) is the most frequent diagnosis made in women with lower genital tract symptoms. It has recently been observed that 90% of subjects with BV show the growth of bacteria in the form of biofilms,and that Gardnerella vaginalis was the predominant species. The propensity of G. vaginalis to form biofilm is clinically relevant because this form of growth allows it to tolerate higher concentrations of certain antibiotics, thus increasing the possibility of recurrent BV even after apparently curative therapy. So new treatment strategies must be used to insure complete cure and prevent recurrence. NAC is an amino acid with strong antioxidant, mucolytic and antibacterial properties, and is produced within the human body.Its effect in biofilms has been tested in several bacteria.

This study aims to test the efficacy of NAC in treatment of BV either alone or in combination with the traditionally used metronidazole. Also the effect of using NAC in prevention of recurrence of BV will be monitored.
Liraglutide has not been found to be directly nephrotoxic in animal studies or clinical trials.  
There have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis in liraglutide-treated patients [see Adverse Reactions (6.2)]. Some of these events were reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration [see Adverse Reactions (6.1)]. Some of the reported events occurred in patients receiving one or more medications known to affect renal function or hydration status. Altered renal function has been reversed in many of the reported cases with supportive treatment and discontinuation of potentially causative agents, including liraglutide. Use caution when initiating or escalating doses of liraglutide in patients with renal impairment [see Use in Specific Populations (8.6)].
Lactated Ringer’s and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. Each 100 mL contains 5 g Dextrose Hydrous, USP*; 600 mg Sodium Chloride, USP (NaCl); 310 mg Sodium Lactate (C3H5NaO3); 30 mg of Potassium Chloride, USP (KCl); and 20 mg Calcium Chloride, USP (CaCl2 · 2H20). It contains no antimicrobial agents. 

Approximate pH 5.0 (4.0 to 6.5).

D-Glucopyranose monohydrate

Dextrose is derived from corn.

Lactated Ringer’s and 5% Dextrose Injection, USP administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 130 mEq sodium, 4 mEq potassium, 2.7 mEq calcium, 109 mEq chloride and 28 mEq lactate. The osmolarity is 525 mOsmol/L (calc). Normal physiologic range is approximately 280 to 310 mOsmol/L. The caloric content is 180 kcal/L.

The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
This post-authorisation safety survey (PASS) is an international, multicentre, naturalistic, descriptive survey to confirm safety of risperidone in daily practice. This is a single-arm, prospective, observational survey to compare the safety profile between groups defined by existing risk or disease factors or patient characteristics. The study duration is 6 months with 4 patient visits. The primary objective of this PASS is to confirm safety, as identified in phase III clinical trials of risperidone, by collecting data when the drug is used under marketed conditions in routine clinical practice. A secondary objective is to evaluate effectiveness and reasons for initiating risperidone. Each investigator is to document data for 4-10 treated patients for whom risperidone long-acting injectable (RLAI) treatment is determined to be clinically indicated. Risperidone long-acting injectable (RLAI) is given as intramuscular injections every 2 weeks. The starting dose of RLAI will be in accordance with the product label (usually 25 mg). If necessary, the dosage of the injection may be increased gradually. Treatment duration is 26 weeks. To ensure continued antipsychotic coverage until the main release of risperidone from the microspheres, previous antipsychotic therapy will be continued concomitantly during the first three weeks of the study.
The present invention relates to a novel class of substituted spirocyclic compounds. re resented Formula (II). These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
The invention discloses an analgesic patch and a preparation method thereof. The analgesic patch is prepared from the following raw materials in parts by weight: 26-36 parts of herba asari cum radice, 26-36 parts of clove, 26-36 parts of cortex cinnamomi, 13-18 parts of scorpio, 0.1-0.6 parts of sesame oil, 3-6 parts of honey, 1-3 parts of white vinegar and 0.5-1.2 parts of Baijiu. The analgesic patch is prepared by the following steps: grinding the herba asari cum radice, the clove, the cortex cinnamomi and the scorpio into fine powder, uniformly mixing according to proportions, sequentially adding the sesame oil, the honey, the white vinegar and the Baijiu, and uniformly stirring, so that a patch in the form of a semi-solid is obtained; and adding the patch to a special small application storage groove, so that the analgesic patch is obtained. The analgesic patch disclosed by the invention can overcome various shortcomings of Western medicines and can take a continuous analgesic effect, and the analgesic patch can greatly reduce toxic and side effects and can avoid the easy generation of addiction. The patch, through a transdermal administration mode in continuous 24h, can continuously relieve pain in patients; and the analgesic patch, which is an external medicine, is free from irritation to the stomach and the intestines of the patient, and the analgesic patch relieves the side effects of medicines. The analgesic patch is also beneficial for compliance medication of the patient.
The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. In addition to the normal diet this group would receive 16gm of branched chain amino acid (BCAA) supplement (Commercial oral BCAA granules) daily in 4 divided doses, keeping the protein levels within the same range of 1.5 gm/Kg/day.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgical dentistry. Local anesthesia is performed with infiltration anesthesia Sol. Ubistesini 4% 1.7 ml according to the hydropreparation method. The mucosal incision is made parallel to the bend of the jaw with an indent of 10-12 mm in the area from canine to canine and 7-10 mm in the area of ​​premolars and molars in the lower jaw, and an incision of the mucous membrane is made parallel to the bend of the jaw with an indent of 8-10 mm in the area from canine to canine and 6-7 mm in the region of premolars and molars in the upper jaw. This mucous flap is peeled off from the incision line to the jaw. The submucosal tissues are moved along the periosteum to a depth of 10 mm in the anterior region, by 6-7 mm in the lateral regions of the lower jaw, by 8 mm in the anterior region, and by 6-7 mm in the lateral regions of the upper jaw. Lay the resulting flap. Soft tissues are mobilized in the area of ​​gum recession zones. The mobilized tissues are fixed with a double-sided suture and a fluid composite material on the teeth in the area of ​​gum recession. The sutures and composite material are removed on the 10th day.EFFECT: method makes it possible to increase the efficiency of simultaneous vestibuloplasty and closure of the gingival recession zone, to ensure the preservation of the created depth of the vestibule of the oral cavity and the closure of recession zones, reliable flap fixation, and ease of postoperative rehabilitation.1 cl, 8 dwg, 2 ex